University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Gastroenterol Clin North Am. 2012 Mar;41(1):47-62. doi: 10.1016/j.gtc.2011.12.007. Epub 2012 Jan 5.
Techniques of endoscopic pseudocyst management continue to evolve, but the principles of proper patient selection and careful consideration of the available therapeutic options remain unchanged. Endoscopic management is considered first-line therapy in the treatment of symptomatic pseudocysts. Clinicians should be vigilant in the evaluation of all peripancreatic fluid collections to exclude the presence of a pancreatic cystic neoplasm and avoid draining an immature collection. Expectant management with periodic observation should be considered for the minimally symptomatic patients, even after the traditional 6 weeks of maturation. Further, symptoms, complications, and expansion on serial imaging should prompt intervention by endoscopic, surgical, or percutaneous methods. Pseudocysts should only be punctured when the wall has had sufficient time to mature and after pseudoaneurysm has been ruled out by careful imaging. Small to moderately sized pseudocysts (< 4–6 cm) that communicate with the pancreatic duct are good candidates for endoscopic transpapillary stenting. For larger lesions requiring transmural drainage, EUS guidance is preferable, but good results can be achieved with ENL. EUS may be particularly useful in permitting drainage in patients with suspected perigastric varices or if an endoscopically visible bulge is not apparent. Necrosis is a significant factor for a worse outcome; aggressive debridement with nasocystic or percutaneous endoscopic gastrostomy-cystic catheter lavage plus manual endoscopic techniques for clearing debris should be used. Endoscopic failure, especially in cases with significant necrosis, should be managed operatively. Percutaneous drainage is a good option for immature infected pseudocysts or in patients who are not optimal candidates for other procedures. Close cooperation between endoscopists, surgeons, interventional radiologists, and other healthcare providers is paramount in successfully managing these patients.
内镜下假性囊肿处理技术不断发展,但适当的患者选择和仔细考虑可用治疗选择的原则保持不变。内镜治疗被认为是治疗有症状假性囊肿的一线治疗方法。临床医生应警惕评估所有胰周液体积聚,以排除胰腺囊性肿瘤的存在,并避免引流不成熟的积聚。对于症状轻微的患者,即使在传统的 6 周成熟后,也应考虑定期观察的期待治疗。此外,症状、并发症和连续影像学上的扩张应促使通过内镜、手术或经皮方法进行干预。只有在壁有足够的时间成熟并且通过仔细成像排除假性动脉瘤后,才能对假性囊肿进行穿刺。与胰管相通的小到中等大小的假性囊肿(<4-6cm)是内镜经乳头支架置入术的良好适应证。对于需要经壁引流的较大病变,EUS 引导是首选,但 ENL 也可以取得良好的效果。EUS 可能特别有用,可以在怀疑胃周静脉曲张的患者中引流,或者在没有明显内镜下可见膨出的情况下。坏死是预后不良的重要因素;应使用经鼻囊肿或经皮内镜胃造口-囊肿导管灌洗联合手动内镜技术进行积极清创。内镜治疗失败,特别是在有明显坏死的情况下,应手术治疗。对于未成熟感染性假性囊肿或不适合其他手术的患者,经皮引流是一个很好的选择。内镜医师、外科医生、介入放射科医生和其他医疗保健提供者之间的密切合作对于成功管理这些患者至关重要。